[Asia Economy Reporter Cho Hyun-ui] Samsung Biologics announced on the 15th that it has signed an additional contract for contract development (CDO) of five immuno-oncology drugs with the domestic bio venture company ImmunOncia.
Samsung Biologics plans to provide all services necessary for new drug development for the five substances to be developed by ImmunOncia, including development, clinical sample production, Investigational New Drug (IND) application submission, preclinical and global clinical reagent production.
This is the second CDO contract between Samsung Biologics and ImmunOncia. The two companies began contract development of the immuno-oncology drug 'IMC-002' in January 2018.
Since Samsung Biologics entered the CDO business in 2018, the total number of cumulative orders to date is 55. Among these, 29 are re-contracts where existing customers have additionally entrusted substance development.
Kim Tae-han, CEO of Samsung Biologics, said, "We will create an environment where we can coexist with biotech companies by serving as an 'incubator' for new drug development."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
